Acquisition Synergy Ashion is part of Exact Sciences Genomic Health, creating an opportunity to cross-sell additional precision oncology tests and expand adoption through existing Exact Sciences channels and health system partnerships.

GEM ExTra Advantage The GEM ExTra assay provides whole exome with full transcriptome analysis, elevating Ashion’s value proposition for large cancer centers seeking comprehensive genomic profiling and potentially driving multi-institution contracts.

Enterprise Reach With a small team, prioritize enterprise-level partnerships with health systems and academic centers, leveraging the Exact Sciences ecosystem for scale and co-marketing.

Clinical Creds CAP accreditation and CLIA certification position Ashion as a reliable partner for clinical trials, payer negotiations, and real-world evidence programs.

Data Interop There is opportunity to offer data integration, analytics, and interoperability services (EHR and LIMS workflows, secure cloud sharing) to research partners and hospitals adopting precision oncology.